National
Pentagon working with gay groups on ‘Don’t Ask’ review
Defense officials seek advice, are ‘open and inclusive’
Defense Secretary Robert Gates and Admiral Mike Mullen (Blade photo by Michael Key)
Gay organizations working to end “Don’t Ask, Don’t Tell” are enjoying an open relationship with the Pentagon working group reviewing the law as they continue to express concerns about the study deviating from its purpose.
Defense Secretary Robert Gates and Chairman of the Joint Chiefs of Staff Adm. Michael Mullen established the working group following a Feb. 2 hearing on Capitol Hill as a way to examine how to implement an end to “Don’t Ask, Don’t Tell,” should Congress repeal the law. The work is expected to be completed Dec. 1.
Alex Nicholson, executive director of Servicemembers United, said his organization has had a positive engagement with the working group since its inception.
“They brought us in — in the very beginning — to initially brief us on what they were planning to do, to answer any questions we had,” he said. “They were very open and inclusive, but not only to us. They were that way with our opposition as well.”
In one such conversation, Nicholson said the working group held a conference call to answer questions about the new regulations that were instituted last month to relax the implementation of “Don’t Ask, Don’t Tell.”
“There was a little bit of a worry, I think, in the beginning that maybe them bringing us in, being so open in answering questions, was a one-time, token gesture,” Nicholson said. “I’m pleased to say now it’s my impression that those worries, at least so far, have been unfounded. The working group has a primary point of contact for us within the Department of Defense, and that point of contact has been extremely open and extremely available.”
Nicholson said Servicemembers United first spoke with someone at the working group to express concern about the group’s mandate and noted it would set a bad precedent to poll the force on potential policy changes.
“The working group responded to that by telling us that the terms of reference have been issued, they are what they are and they don’t have control over them,” he said.
In a second round of suggestions, Nicholson said Servicemembers United passed along some ideas for the methodology the working group could institute to examine how to implement repeal. Some of the recommendations, he noted, were to advise against town hall meetings and focus groups to poll the force.
“Focus groups are a bad idea because of the phenomena of group think and posturing,” he said. “On any perceived controversial issue, you’re going to get a much a different set of answers if you ask people about it in a group rather than asking them one on one.”
Aubrey Sarvis, executive director of the Servicemembers Legal Defense Network, also said his organization’s staff have had weekly conversations and meetings with the working group.
“I think it’s been positive, ongoing,” he said. “It’s not a process that we asked for, or that we think is needed, but we’re dealing with the reality that it’s in place and we’re going to do everything that we can to make it work and have a positive contribution.”
In these conversations, Sarvis said SLDN has been recommending voices and organizations that work to end the ban on open service.
Another organization that has engaged with the working group is the Palm Center, a think tank on gays in the military at the University of California, Santa Barbara. Nathaniel Frank, a Palm Center research fellow, said he’s had a “good relationship” with the Pentagon working group.
“They’ve reached out to us consistently and they’ve been responsive to us and I’m impressed by that,” he said. “The question will be, obviously, what are the results of the study and how are they expressed. So that proof will be in the pudding.”
Frank said the working group has asked the Palm Center to make recommendations on a litany of issues, including how to identify the costs to the military of “Don’t Ask, Don’t Tell.”
“That doesn’t mean just financial costs,” he said. “It means a litany of costs to morale, recruitment, cohesion, the impact on GLB service members, and Palm is coming out with a memo that I’m finalizing now that tries to convey all of those costs.”
Frank said the working group also asked about the pitfalls of using focus groups; how to measure the views of military families; and how to empirically assess the impact of lifting the ban on unit cohesion.
Another item that Frank said he was asked about was getting the views of gay service members for the study without putting them at risk for discharge under “Don’t Ask, Don’t Tell.”
This challenge has been repeatedly discussed in hearings on Capitol Hill and among those seeking repeal. In a statement released last week, Army Secretary John McHugh said the Pentagon is “likely” to employ a third party to solicit those views.
Sarvis said his understanding is the Pentagon is considering the use of a professional consultant or pollsters who have worked with the Pentagon before on manpower issues.
“In addition, I think they’re also looking to the RAND Corp. as part of that engagement,” he said.
But the decision on how the Defense Department will obtain these views is apparently not yet final. Cynthia Smith, a Pentagon spokesperson, said in a statement to DC Agenda on April 9 that the working group is still considering the best way to incorporate gay service members into the study.
“Getting the views of gay and lesbian service members is very important to the working group,” she said. “We are still in the process of developing the proper instrument to obtain this information from gay and lesbian service members currently serving.”
Frank said he would take issue with any decision from the Pentagon to use a third party to solicit the views of gay service members because it would create a situation where service members generally would speak to one group, and gay, lesbian and bisexual service members would talk to another.
“Uniform personnel … would be consulting service members generally and then they would employ civilians or a third party only to speak to known gays and lesbians,” he said. “There’s an unfairness there in having the military speak directly to straight service members and not to gay service members.”
A better solution, Frank said, would be for the Pentagon to issue new regulations that would enable all service members to speak to the working group without fear of being discharged under “Don’t Ask, Don’t Tell.”
“The only consistent way to do it is to apply that uniformly to all people and not have separate standards, which is obviously the problem with the policy as it is,” he said.
Even with the openness between these groups and Pentagon officials, some repeal advocates say they have concerns about the working group’s direction.
Gates has repeatedly said the purpose of the group will be to examine how to implement an end to the ban should Congress repeal the law during the Senate hearing in February. But some repeal advocates say there’s a lack of clarity.
Nicholson said he has “big concerns” about the direction the group is heading, recalling testimony that Jeh Johnson, head of the Pentagon’s Office of General Counsel and co-chair of the group, gave before the House in March in which the results of the working group would inform how Congress would proceed on the issue.
“And that, I think, was very dangerous and was a new twist,” he said. “If the mission of the working group is to simply come up with an effective implementation management plan for after repeal takes effect, then there really should be no reason why Congress should need to wait for the outcome of the working group.”
Frank also acknowledged “some confusion” about whether the purpose of the working group is to study how to lift the ban or whether to lift the ban.
“I think the reason for that confusion is while the group says it’s studying how to lift the ban, given the strategic intention of the president, whether the ban is actually lifted is in the hands of the Congress,” Frank said. “So if the group comes out with a study that exaggerates the risks to cohesion, or other risks associated with lifting the ban, obviously, that will make it easier for obstructionists in Congress to try to block repeal.”
Frank called on leaders handling the group to “make it more clear that they are assessing how best to lift the ban” and note that the only reason they’re evaluating repeal is to determine how to mitigate any harm.
“It’s important to say that years and years of research across the board make clear that that impact will be negligible or non-existent, and most of us already know that,” he said.
Nicholson was particularly critical of the White House and said he thinks it’s “extremely concerning” President Obama hasn’t come out and clarified the study’s purpose. Nicholson noted that he’s been asking for clarification from the White House for several weeks now and hasn’t received a response.
“I just felt like with the working group, they’ve been very much great in communicating with us, been very receptive, I do get the impression that they’re honestly considering the suggestions we give to them,” he said. “The White House, on the other hand, it’s felt like we’ve been throwing suggestions down a black hole.”
Nicholson said he doesn’t think that White House officials are seriously considering his organization’s input and that “they ignore a lot of us for weeks at a time sometimes.”
“Unfortunately, the White House is not only not listening to or considering our suggestions and communicating with us, but they haven’t given any indication that they intend to clarify the position of the working group or curtail the expansion of its scope,” he said.
Shin Inouye, a White House spokesperson, disputed the notion that the White House wasn’t engaged with the Servicemembers United.
“The White House is actively engaged with Servicemembers United and other groups on many issues of interest to the LGBT community, including ‘Don’t Ask, Don’t Tell,'” he said in a statement.
But Sarvis said he thinks the group will stay on track with its mission as long as it adheres to its mandate and stays focused on implementing open service.
“If they move away from their mandate, if they get into polling on if or whether, or seeking the personal opinions of service members, then, yes,” he said, “I think we have a problem.”
Federal Government
Holiday week brings setbacks for Trump-Vance trans agenda
Federal courts begin to deliver end-of-year responses to lawsuits involving federal transgender healthcare policy.
While many Americans took the week of Christmas to rest and relax, LGBTQ politics in the U.S. continued to shift. This week’s short recap of federal updates highlights two major blows to the Trump-Vance administration’s efforts to restrict gender-affirming care for minors.
19 states sue RFK Jr. to end gender-affirming care ban
New York Attorney General Letitia James announced on Tuesday that the NYAG’s office, along with 18 other states (and the District of Columbia), filed a lawsuit to stop U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. from restricting gender-affirming care for minors.
In the press release, Attorney General James stressed that the push by the Trump-Vance administration’s crusade against the transgender community — specifically transgender youth — is a “clear overreach by the federal government” and relies on conservative and medically unvalidated practices to “punish providers who adhere to well-established, evidence-based care” that support gender-affirming care.
“At the core of this so-called declaration are real people: young people who need care, parents trying to support their children, and doctors who are simply following the best medical evidence available,” said Attorney General James. “Secretary Kennedy cannot unilaterally change medical standards by posting a document online, and no one should lose access to medically necessary health care because their federal government tried to interfere in decisions that belong in doctors’ offices. My office will always stand up for New Yorkers’ health, dignity, and right to make medical decisions free from intimidation.”
The lawsuit is a direct response to HHS’ Dec. 18 announcement that it will pursue regulatory changes that would make gender-affirming health care for transgender children more difficult, if not impossible, to access. It would also restrict federal funding for any hospital that does not comply with the directive. KFF, an independent source for health policy research, polling, and journalism, found that in 2023 federal funding covered nearly 45% of total spending on hospital care in the U.S.
The HHS directive stems directly from President Donald Trump’s Jan. 28 Executive Order, Protecting Children From Chemical and Surgical Mutilation, which formally establishes U.S. opposition to gender-affirming care and pledges to end federal funding for such treatments.
The American Medical Association, the nation’s largest and most influential physician organization, has repeatedly opposed measures like the one pushed by President Trump’s administration that restrict access to trans health care.
“The AMA supports public and private health insurance coverage for treatment of gender dysphoria and opposes the denial of health insurance based on sexual orientation or gender identity,” a statement on the AMA’s website reads. “Improving access to gender-affirming care is an important means of improving health outcomes for the transgender population.”
The lawsuit also names Oregon, Washington, California, Colorado, Connecticut, Delaware, the District of Columbia, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Mexico, Pennsylvania, Rhode Island, Vermont, and Wisconsin as having joined New York in the push against restricting gender-affirming care.
At the HHS news conference last Thursday, Jim O’Neill, deputy secretary of the department, asserted, “Men are men. Men can never become women. Women are women. Women can never become men.”
DOJ stopped from gaining health care records of trans youth
U.S. District Judge Cathy Bissoon blocked an attempt by the Department of Justice (DOJ) to gain “personally identifiable information about those minor transgender patients” from the University of Pittsburgh Medical Center (UPMC), saying the DOJ’s efforts “fly in the face of the Supreme Court.”
Journalist Chris Geidner originally reported the news on Dec. 25, highlighting that the Western District of Pennsylvania judge’s decision is a major blow to the Trump-Vance administration’s agenda to curtail transgender rights.
“[T]his Court joins the others in finding that the government’s demand for deeply private and personal patient information carries more than a whiff of ill intent,” Bissoon wrote in her ruling. “This is apparent from its rhetoric.”
Bissoon cited the DOJ’s “incendiary characterization” of trans youth care on the DOJ website as proof, which calls the practice politically motivated rather than medically sound and seeks to “…mutilate children in the service of a warped ideology.” This is despite the fact that a majority of gender-affirming care has nothing to do with surgery.
In United States v. Skrmetti, the Supreme Court ruled along party lines that states — namely Tennessee — have the right to pass legislation that can prohibit certain medical treatments for transgender minors, saying the law is not subject to heightened scrutiny under the Equal Protection Clause of the Fourteenth Amendment because it does not involve suspect categories like race, national origin, alienage, and religion, which would require the government to show the law serves a compelling interest and is narrowly tailored, sending decision-making power back to the states.
“The government cannot pick and choose the aspects of Skrmetti to honor, and which to ignore,” Judge Bissoon added.
The government argued unsuccessfully that the parents of the children whose records would have been made available to the DOJ “lacked standing” because the subpoena was directed at UPMC and that they did not respond in a timely manner. Bissoon rejected the timeliness argument in particular as “disingenuous.”
Bissoon, who was nominated to the bench by then-President Obama, is at least the fourth judge to reject the DOJ’s attempted intrusion into the health care of trans youth according to Geidner.
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
Holiday week brings setbacks for Trump-Vance trans agenda
Your guide to D.C.’s queer New Year’s Eve parties
Long-awaited ‘Pillion’ surpasses the sexy buzz
Trump’s ‘American people derangement syndrome’
Reasons to be optimistic about 2026
Reasons to be optimistic about 2026
America is going in the wrong direction for intersex children
Long-awaited ‘Pillion’ surpasses the sexy buzz
Protecting the trans community is not optional for elected allies and candidates
Trump’s ‘American people derangement syndrome’
-
District of Columbia3 days agoReasons to be optimistic about 2026
-
Commentary5 days ago
America is going in the wrong direction for intersex children
-
Movies3 days ago
Long-awaited ‘Pillion’ surpasses the sexy buzz
-
Commentary4 days ago
Protecting the trans community is not optional for elected allies and candidates
